Renaissance Technologies LLC Has $1.97 Million Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Renaissance Technologies LLC grew its stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 483.8% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 466,437 shares of the biotechnology company's stock after buying an additional 386,537 shares during the period. Renaissance Technologies LLC owned approximately 0.55% of Anavex Life Sciences worth $1,968,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in AVXL. SG Americas Securities LLC acquired a new stake in Anavex Life Sciences during the second quarter worth $57,000. Fiduciary Alliance LLC bought a new stake in Anavex Life Sciences in the first quarter valued at about $67,000. China Universal Asset Management Co. Ltd. raised its position in Anavex Life Sciences by 66.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 15,773 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 6,275 shares in the last quarter. Belpointe Asset Management LLC bought a new position in Anavex Life Sciences during the fourth quarter worth about $93,000. Finally, EntryPoint Capital LLC boosted its holdings in Anavex Life Sciences by 371.1% during the first quarter. EntryPoint Capital LLC now owns 20,007 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 15,760 shares in the last quarter. Institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Trading Down 1.0 %

Shares of Anavex Life Sciences stock traded down $0.06 during trading on Thursday, reaching $5.60. The company's stock had a trading volume of 492,162 shares, compared to its average volume of 1,194,273. The stock has a 50-day moving average price of $5.96 and a two-hundred day moving average price of $4.91. Anavex Life Sciences Corp. has a one year low of $3.25 and a one year high of $10.45. The stock has a market capitalization of $474.00 million, a P/E ratio of -11.26 and a beta of 0.62.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. During the same period in the prior year, the firm earned ($0.14) earnings per share. As a group, sell-side analysts anticipate that Anavex Life Sciences Corp. will post -0.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. EF Hutton Acquisition Co. I upgraded Anavex Life Sciences to a "strong-buy" rating in a research report on Monday, July 22nd. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Anavex Life Sciences in a report on Thursday, August 1st.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.